LncRNA CAIF was downregulated in end-stage cardiomyopathy and is a promising diagnostic and prognostic marker for this disease

Biomarkers. 2019 Dec;24(8):735-738. doi: 10.1080/1354750X.2019.1677778. Epub 2019 Oct 17.

Abstract

Cardiac autophagy inhibitory factor (CAIF) is a novel lncRNA with protective effects on myocardial infarction. We explored the involvement of CAIF in end-stage cardiomyopathy. Patients with end-stage cardiomyopathy and healthy volunteers were included in this study. Myocardial tissues and serum were collected. CAIF was detected by RT-qPCR. ROC curve was used for diagnostic analysis. Prognostic value of CAIF expression for end-stage cardiomyopathy was evaluated by survival curve analysis. Correlations between CAIF expression and clinicopathological data of patients with end-stage cardiomyopathy were analysed by chi-square test. Downregulated CAIF was observed in end-stage cardiomyopathy patients than in healthy controls. CAIF expression distinguished end-stage cardiomyopathy patients from healthy controls and predict the survival of patients. LncRNA CAIF was downregulated in end-stage cardiomyopathy and may serve as a promising prognostic and diagnostic marker for this disease.

Keywords: End-stage cardiomyopathy; diagnosis; lncRNA CAIF; prognosis.

MeSH terms

  • Autophagy / drug effects
  • Biomarkers / analysis
  • Cardiomyopathies / diagnosis*
  • Cardiomyopathies / genetics
  • Cardiomyopathies / pathology
  • Case-Control Studies
  • Humans
  • Prognosis
  • RNA, Long Noncoding / analysis
  • RNA, Long Noncoding / metabolism*
  • RNA, Long Noncoding / pharmacology

Substances

  • Biomarkers
  • RNA, Long Noncoding